Efficacy and safety of drug-coated balloon in the treatment of acute myocardial infarction: a meta-analysis of randomized controlled trials

Acute myocardial infarction (AMI) is one of the main causes of death in the world, and the incidence of AMI is increasing in the young population. Drug-coated balloon (DCB) has become an effective concept for the treatment of in-stent restenosis, small vessel disease, bifurcation lesions, high blood...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-04, Vol.12 (1), p.6552-6552, Article 6552
Main Authors: Li, Qiu-Yi, Chang, Mei-Ying, Wang, Xin-Yi, Wang, An-Lu, Liu, Qi-Yu, Wang, Tong, Xu, Hao, Chen, Ke-Ji
Format: Article
Language:English
Subjects:
692/4019
692/4019/2776
Angioplasty, Balloon, Coronary - adverse effects
Balloon treatment
Clinical trials
Coated Materials, Biocompatible
Coronary Artery Disease - etiology
Coronary Restenosis - etiology
Heart attacks
Humanities and Social Sciences
Humans
Implants
Lesions
Meta-analysis
multidisciplinary
Myocardial infarction
Myocardial Infarction - complications
Patients
Randomized Controlled Trials as Topic
Restenosis
Science
Science (multidisciplinary)
Stents
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute myocardial infarction (AMI) is one of the main causes of death in the world, and the incidence of AMI is increasing in the young population. Drug-coated balloon (DCB) has become an effective concept for the treatment of in-stent restenosis, small vessel disease, bifurcation lesions, high blood risk conditions, and even de novo large vessel disease. To ensure whether DCB can play an alternative role in AMI, we conducted a comprehensive meta‐analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of DCB in the treatment of AMI. Electronic databases were searched for RCTs that compared DCB with stent for AMI. The primary outcome was major adverse cardiac events (MACEs), the secondary outcome was late lumen loss (LLL). RevMan 5.3 software and RStudio software were used for data analysis. Five RCTs involving 528 patients with 6–12 months of follow-up were included. There was no significant difference in the incidence of MACEs between DCB group and stent group (RR, 0.85; 95% CI 0.42 to 1.74; P  = 0.66). Lower LLL was shown in DCB group (WMD, − 0.29; 95% CI − 0.46 to − 0.12; P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-10124-z